Modified Probiotic Yeast Enhances Safety for Vulnerable Populations
An international research team has engineered a probiotic yeast to improve safety for immunocompromised patients, older adults, and infants, as demonstrated in animal model testing.
Recent advancements in genetic modification have led to the development of a probiotic yeast designed specifically for immunocompromised individuals. This modification aims to mitigate infection risks associated with probiotic use in vulnerable populations.
The research, conducted by an international team, utilized animal models to assess the safety and efficacy of the modified yeast. Results indicated a significant reduction in infection likelihood compared to traditional strains.
Target groups for this enhanced probiotic include older adults and infants, who are particularly susceptible to infections. The implications of this research could lead to safer probiotic options in clinical settings.